Clene (CLNN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, with voting available online or in person until May 20, 2026.
Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.
Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 annual meeting: Robert Etherington, Shalom Jacobovitz, and Alison H. Mosca.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
Advisory approval of compensation for Named Executive Officers.
Approval of an amendment to the Amended 2020 Stock Plan to increase reserved shares by 1,000,000.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Latest events from Clene
- Shareholders will vote on director elections, auditor ratification, executive pay, and stock plan expansion.CLNN
Proxy filing10 Apr 2026 - Net loss narrowed in 2025, with strong financing and positive ALS biomarker data supporting NDA plans.CLNN
Q4 202512 Mar 2026 - Strong biomarker and survival data for ALS therapy positions company for NDA filing and 2027 launch.CLNN
Emerging Growth Virtual Conference25 Feb 2026 - FDA to review ALS therapy data this quarter; NDA filing and commercialization targeted for 2025.CLNN
Emerging Growth Conference 8921 Jan 2026 - Accelerated approval for ALS is being pursued with robust neurofilament and survival data.CLNN
37th Annual ROTH Conference26 Dec 2025 - Registering 2.35M shares for resale as clinical-stage neurology biotech faces funding risks.CLNN
Registration Filing16 Dec 2025 - Registering shares for resale after note conversion; no proceeds to company; urgent funding needs.CLNN
Registration Filing16 Dec 2025 - Biotech aims to raise $160M for neurodegenerative drug trials amid urgent funding needs.CLNN
Registration Filing16 Dec 2025 - Registering shares for resale amid urgent funding needs and advancing neurodegenerative drug trials.CLNN
Registration Filing16 Dec 2025